Overview
Lobbying Costs
100,000€ - 199,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
0.2 Fte (2)
Lobbyists with EP accreditation
1
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
The Employers' Union of Innovative Pharmaceutical Companies (INFARMA)
EU Transparency Register
707197749527-51 First registered on 21 Mar 2023
Goals / Remit
The Employers' Union of Innovative Pharmaceutical Companies INFARMA represents 24 leading pharmaceutical companies engaged in research and development activities and the production of innovative medicines.
INFARMA’s objective is taking initiatives which positively influence the creation of system solutions in the field of healthcare and promoting innovation resulting from research and original medicinal products in accordance with the principles of medicine based on evidence. Such solutions should allow patients access to modern and the most effective treatments so that Polish norms of treatment meet the global standards.
In particular, it aims to foster an environment that encourages pharmaceutical research and development, manufacture in compliance with high-quality standards, intellectual property protection and the introduction of regulatory requirements to allow patients rapid access to medicinal products.Main EU files targeted
Any health or pharmaceutical policy stemming from the European institutions, such as - but not exclusive - Industrial Policy, Pharmaceutical Strategy, pharmaceutical, orphan and paediatrics legislation, Horizon Europe Research Programme, HTA policy, IP policy, One Health Approach to tackle AMR, COVID-19 outbreak measures.
Main EU legislative proposals or policies targeted (a non-exhaustive list):
- A Pharmaceutical Strategy for Europe – over 50 legislative and non-legislative proposals
- Directive 2001/83/EC on the Community code relating to medicinal products for human use
- Regulation (EC) No 726/2004 of the European Parliament and of the Council laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency
- Regulation (EC) No 141/2000 of the European Parliament and of the Council on orphan medicinal products.
- Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use
In addition, we also follow for example:
- Clinical Trial Regulation
- EMA Fees Regulation
- Europe’s Beating Cancer Plan
- European Health Data Space
- HERA Regulation
- SPCs Regulation revision
- IP Action PlanAddress
Head Office
ul.Jasna 14/16A
Warszawa 00-041 - Warszawa
POLANDEU Office
ul.Jasna 14/16A
Warszawa 00-041 - Warszawa
POLANDWebsite
-
People
Total lobbyists declared
2
Employment time Lobbyists 10% 2 Lobbyists (Full time equivalent)
0.2
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
1 accreditations were / are live (in bold) for the selected state of 05 Jan 2025
Name Start date End Date Anna Kacprzyk 04 Nov 2024 03 Nov 2025 Mr Michal BYLINIAK 13 Apr 2023 26 Apr 2024 Ms Anna KACPRZYK 13 Apr 2023 26 Apr 2024 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Trade and business associations
-
Networking
Affiliation
European Federation of Pharmaceutical Industries and Associations
https://www.efpia.eu/
Employers of Poland
https://pracodawcyrp.pl/
National Chamber of Commerce
https://kig.pl/Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
100,000€ - 199,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount viewpointgroup 10,000€ - 24,999€ Intermediaries for current year
Name cec Closed year Costs
100,000€ - 199,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
INFARMA communications activities include:
- Publishing new evidence (etc. reports, leaflets, infographics)
- Preparing and communicating letters, information material or discussion papers and position papers,
- Organising events, meetings, promotional activities, conferences or social events,
- Disseminating our key messages through media and social media,
- Participation in formal consultations or hearings in the EU legislative.Other activities
None declared
Meetings
Meetings
None declared